

Wednesday, April 24, 2019

LSC 3 | 12:00 - 1:00PM



Dr. Gavin Y. Oudit

Professor, Department of Medicine, University of Alberta
Clinician-Scientist, Mazankowski Alberta Heart Institute
Director, Heart Function Clinic
Director, Human Explanted Heart Program (HELP)
Canada Research Chair, Heart Failure

“Pathophysiology of Iron-Overload Cardiomyopathy: Role of Resveratrol and Amlodipine as Novel Therapies”

Primary hemochromatosis and secondary iron overload conditions, such as thalassemia and sickle cell anemia, result in iron overload and are among the most frequently inherited disorders at an international scale. The prevalence and global clinical burden of iron overload is high resulting in heart and liver diseases. Iron-overload cardiomyopathy is a common cause of mortality in patients with secondary iron overload and is a major comorbidity in patients with primary hemochromatosis. Elucidating the basis pathophysiology of iron-overload mediated injury has provided new insights into potential new therapies for patients with iron overload. We will discuss the potential use of calcium channel blockade and resveratrol therapy for iron overload conditions.

Live Online Seminar Viewing:
<https://meet.ubc.ca/hana.kim/YGHMR41Q>



Canadian
Blood
Services

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

